FierceBiotech (@fiercebiotech) 's Twitter Profile
FierceBiotech

@fiercebiotech

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

ID: 18294197

linkhttp://FierceBiotech.com calendar_today21-12-2008 22:21:58

29,29K Tweet

101,101K Followers

636 Following

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Rallybio’s lead program has crashed out. Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare maternal immune disorder in response to phase 2 data. $RLYB fiercebiotech.com/biotech/rallyb…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

A US congressional commission has made the case for ā€œswift actionā€ to maintain the nation’s role as a biotech superpower, while warning the sector is ā€œdangerously close to falling behind China.ā€ fiercebiotech.com/biotech/congre…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

With two attempts to merge with other companies having collapsed, Vincerx Pharma has been left with no choice but to start winding down. $VINC fiercebiotech.com/biotech/vincer…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Valiltramiprosate was no better than placebo at slowing cognitive decline in the phase 3 trial, causing the study—which included 325 people with early Alzheimer’s—to miss its primary endpoint. fiercebiotech.com/biotech/alzheo…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

ā€œNo one was saying 2025 was going to be an awesome year for biotech IPOs, in particular,ā€ Adam Farlow, Global Chair of Baker McKenzie’s Capital Markets Practice Group, told James Waldron. ā€œLast week's announcements created additional volatility. Equity markets hate volatility,

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticariaĀ drug into phase 2, instead preparing to sell the asset while liquidating the business. fiercebiotech.com/biotech/third-…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX40-ligand monoclonal antibody missed the main goal of a phase 2 asthma study. $SNY fiercebiotech.com/biotech/sanofi…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Essa Pharma is facing a call to wind down operations. One of the biotech’s largest shareholdersĀ put the proposal to Essa’s board after concluding that the best option is to return cash to investors. $EPIX fiercebiotech.com/biotech/invest…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. $LLY fiercebiotech.com/biotech/lillys…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Nine months after Johnson & Johnson stepped back from an Addex Therapeutics-partnered epilepsy drug in the wake of a phase 2 fail, the Big Pharma has now fully severed its relationship with the Swiss biotech. #ADXN $JNJ fiercebiotech.com/biotech/jj-cal…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

VelaVigo Bio has landed its second deal in six months,Ā offloading ex-China rights to a bispecific to Ollin Biosciences for up to $440 million. fiercebiotech.com/biotech/stealt…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

The US government has terminated a $4.2M contract for Pluri Biotech’s PLX-R18 cell therapy in a move that the biotech believes ā€œmay reflect broader federal budgetary and administrative adjustments." fiercebiotech.com/biotech/nih-ni…

Ian Kremer (@lead_coalition) 's Twitter Profile Photo

New #NIH grant rules override the Civil Rights Act of 1964, barring recipients from DEI activities fiercebiotech.com/research/new-n… by FierceBiotech #Alzheimers #dementia #science

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Sanofi’s development of an oral spin on Humira’s mechanism has fallen short in a ph. 2 psoriasis trial, prompting the French drugmaker to pull back from plans to develop the molecule as a monotherapy. $SNY fiercebiotech.com/biotech/sanofi…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

A study of almost 34,000 people in rural China has revealed that lowering blood pressure can reduce the risk of dementia in patients with hypertension. fiercebiotech.com/research/massi…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Spruce Biosciences hasĀ swept away 55% of its employees. The biotech took the action days after inking a deal for a former BioMarin rare disease candidate that it plans to file for a speedy approval next year. fiercebiotech.com/biotech/spruce…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

The HHS has lifted a stop work order on Vaxart’s phase 2b trial testing out a COVID-19 vaccine pill, with the biotech resuming plans to enroll participants for the 10,000-person study. $VXRT fiercebiotech.com/biotech/hhs-li…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program and running into unresolved biology questions. fiercebiotech.com/biotech/octago…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Pink slips have followed the green light at Entrada Therapeutics. Weeks after the FDA lifted a more than two-year-long hold, the biotech hasĀ set out plans to reduce its workforce by 20%. $TRDA fiercebiotech.com/biotech/entrad…

FierceBiotech (@fiercebiotech) 's Twitter Profile Photo

Pfizer and Arvinas haveĀ axed two phase 3 trials from their estrogen receptor degrader R&D plan in the wake of mixed data. Arvinas is also is laying off a third of its staff to cut costs and extend its cash runway. $PFE $ARVN fiercebiotech.com/biotech/arvina…